Erratum: safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment (Journal of Rheumatology (2019) 46 (7-18) DOI: 10.3899/jrheum.171361)

In Table 1, Phase II, NCT01469013 is mentioned twice. The second occurrence is unnecessary. In the Results section, page 9, last paragraph, the first sentence should read as follows: The herpes zoster IR was significantly higher for 4 mg compared to placebo (4.3 vs 1.0) and was numerically higher for 4 mg compared to 2 mg in 2 mg‐4 mg.extended. Bold face indicates words added for clarity. Table 4. Adverse events (AE) detail. • Three AE (EAIR ≥ 0.2) and their data have been added under the category Temporary interruption because of AE ≥ 0.2 EAIR for 4 mg.treated patients in placebo‐4 mg, n (EAIR). See below. • Under the category Permanent discontinuation because of AE ≥ 0.2 EAIR for 4 mg.treated patients in placebo‐4 mg, n (EAIR) in the row for infections and infestations, under the 2mg‐4mg‐extended set, for baricitinib 4 mg, the p value is < 0.05, indicating significance. Table 5. The corrected table is below. Changes are indicated in bold face. • HDL numbers have been corrected. • Units for hemoglobin were corrected to g/dl. • Hemoglobin < 10 g/dl: the corrected values for baricitinib 2 mg and baricitinib 4 mg under the Placebo‐2 mg.4 mg set are 33/462 (7.1) and 35/467 (7.5), respectively. • In the Placebo‐4 mg set, under Baricitinib 4 mg, the corrected values for ALT > 3x ULN are 15/987 (1.5), and for ALT ≥ 5x ULN, 7/988 (0.7) (Table Presented).